Interim 2023/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom

Interim 2023/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom

<p><strong>Background: </strong>We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England.</p> <p><strong>Methods: &...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Whitaker, H, Findlay, B, Zitha, J, Goudie, R, Hassell, K, Evans, J, Kalapotharakou, P, Agrawal, U, Kele, B, Hamilton, M, Moore, C, Byford, R, Stowe, J, Robertson, C, Couzens, A, Jamie, G, Hoschler, K, Pheasant, K, Button, E, Quinot, C, Jones, T, Anand, S, Watson, C, Andrews, N, de Lusignan, S, Zambon, M, Williams, C, Cottrell, S, Marsh, K, McMenamin, J, Lopez Bernal, J
Formato:	Journal article
Idioma:	English
Publicado em:	Wiley 2024

Descrição
Resumo:	<p><strong>Background: </strong>We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England.</p> <p><strong>Methods: </strong>A test negative design was used to estimate vaccine effectiveness.</p> <p><strong>Results: </strong>Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2–17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18–64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over.</p> <p><strong>Conclusions: </strong>During a period of co-circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.</p>